| Year |
Citation |
Score |
| 2024 |
Boulet S, Ursino M, Michelet R, Aulin LB, Kloft C, Comets E, Zohar S. Bayesian framework for multi-source data integration-Application to human extrapolation from preclinical studies. Statistical Methods in Medical Research. 9622802241231493. PMID 38446999 DOI: 10.1177/09622802241231493 |
0.32 |
|
| 2023 |
Duputel B, Stallard N, Montestruc F, Zohar S, Ursino M. Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial. Statistical Methods in Medical Research. 9622802231160554. PMID 36919403 DOI: 10.1177/09622802231160554 |
0.321 |
|
| 2023 |
Vanier A, Fernandez J, Kelley S, Alter L, Semenzato P, Alberti C, Chevret S, Costagliola D, Cucherat M, Falissard B, Gueyffier F, Lambert J, Lengliné E, Locher C, Naudet F, ... ... Zohar S, et al. Rapid access to innovative medicinal products while ensuring relevant health technology assessment. Position of the French National Authority for Health. Bmj Evidence-Based Medicine. PMID 36788020 DOI: 10.1136/bmjebm-2022-112091 |
0.474 |
|
| 2022 |
Lambert J, Lengliné E, Porcher R, Thiébaut R, Zohar S, Chevret S. Enriching single-arm clinical trials with external controls: possibilities and pitfalls. Blood Advances. PMID 36534147 DOI: 10.1182/bloodadvances.2022009167 |
0.486 |
|
| 2022 |
Röver C, Ursino M, Friede T, Zohar S. A straightforward meta-analysis approach for oncology phase I dose-finding studies. Statistics in Medicine. PMID 35661205 DOI: 10.1002/sim.9484 |
0.354 |
|
| 2021 |
Gerard E, Zohar S, Lorenzato C, Ursino M, Riviere MK. Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens. Statistics in Medicine. PMID 34259343 DOI: 10.1002/sim.9113 |
0.43 |
|
| 2021 |
Ollier A, Zohar S, Morita S, Ursino M. Estimating Similarity of Dose-Response Relationships in Phase I Clinical Trials-Case Study in Bridging Data Package. International Journal of Environmental Research and Public Health. 18. PMID 33572323 DOI: 10.3390/ijerph18041639 |
0.451 |
|
| 2021 |
Gerard E, Zohar S, Thai HT, Lorenzato C, Riviere MK, Ursino M. Bayesian dose-regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics. Biometrics. PMID 33527351 DOI: 10.1111/biom.13433 |
0.357 |
|
| 2020 |
Murray TA, Thall PF, Schortgen F, Asfar P, Zohar S, Katsahian S. Robust Adaptive Incorporation of Historical Control Data in a Randomized Trial of External Cooling to Treat Septic Shock. Bayesian Analysis. 16: 825-844. PMID 36277025 DOI: 10.1214/20-ba1229 |
0.567 |
|
| 2020 |
Stallard N, Hampson L, Benda N, Brannath W, Burnett T, Friede T, Kimani PK, Koenig F, Krisam J, Mozgunov P, Posch M, Wason J, Wassmer G, Whitehead J, Williamson SF, ... Zohar S, et al. Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. Statistics in Biopharmaceutical Research. 12: 483-497. PMID 34191981 DOI: 10.1080/19466315.2020.1790415 |
0.315 |
|
| 2020 |
Dequin PF, Gouge AL, Tavernier E, Giraudeau B, Zohar S. Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience. Statistics in Biopharmaceutical Research. 12: 478-482. PMID 34191980 DOI: 10.1080/19466315.2020.1800509 |
0.328 |
|
| 2020 |
Kunz CU, Jörgens S, Bretz F, Stallard N, Van Lancker K, Xi D, Zohar S, Gerlinger C, Friede T. Clinical Trials Impacted by the COVID-19 Pandemic: Adaptive Designs to the Rescue? Statistics in Biopharmaceutical Research. 12: 461-477. PMID 34191979 DOI: 10.1080/19466315.2020.1799857 |
0.327 |
|
| 2020 |
Dequin PF, Heming N, Meziani F, Plantefève G, Voiriot G, Badié J, François B, Aubron C, Ricard JD, Ehrmann S, Jouan Y, Guillon A, Leclerc M, Coffre C, Bourgoin H, ... ... Zohar S, et al. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. Jama. PMID 32876689 DOI: 10.1001/Jama.2020.16761 |
0.35 |
|
| 2020 |
Murray TA, Thall PF, Schortgen F, Zohar S, Katsahian S. Robust Adaptive Incorporation of Historical Control Data in a Randomized Trial of External Cooling to Treat Septic Shock Bayesian Analysis. DOI: 10.1214/20-Ba1229 |
0.605 |
|
| 2020 |
Dequin P, Gouge AL, Tavernier E, Giraudeau B, Zohar S. Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience Statistics in Biopharmaceutical Research. 1-5. DOI: 10.1080/19466315.2020.1800509 |
0.428 |
|
| 2020 |
Kunz CU, Jörgens S, Bretz F, Stallard N, Lancker KV, Xi D, Zohar S, Gerlinger C, Friede T. Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue? Statistics in Biopharmaceutical Research. 1-17. DOI: 10.1080/19466315.2020.1799857 |
0.331 |
|
| 2020 |
Stallard N, Hampson L, Benda N, Brannath W, Burnett T, Friede T, Kimani PK, Koenig F, Krisam J, Mozgunov P, Posch M, Wason J, Wassmer G, Whitehead J, Williamson SF, ... Zohar S, et al. Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19 Statistics in Biopharmaceutical Research. 1-15. DOI: 10.1080/19466315.2020.1790415 |
0.384 |
|
| 2020 |
Diao G, Vidyashankar AN, Zohar S, Katsahian S. Competing Risks Model with Short-Term and Long-Term Covariate Effects for Cancer Studies Statistics in Biosciences. 1-18. DOI: 10.1007/S12561-020-09288-X |
0.554 |
|
| 2019 |
Ollier A, Morita S, Ursino M, Zohar S. An adaptive power prior for sequential clinical trials - Application to bridging studies. Statistical Methods in Medical Research. 962280219886609. PMID 31729275 DOI: 10.1177/0962280219886609 |
0.42 |
|
| 2019 |
Aupiais C, Alberti C, Schmitz T, Baud O, Ursino M, Zohar S. A Bayesian non-inferiority approach using experts' margin elicitation - application to the monitoring of safety events. Bmc Medical Research Methodology. 19: 187. PMID 31533631 DOI: 10.1186/S12874-019-0826-5 |
0.565 |
|
| 2019 |
Favrais G, Ursino M, Mouchel C, Boivin E, Jullien V, Zohar S, Saliba E. Levetiracetam optimal dose-finding as first-line treatment for neonatal seizures occurring in the context of hypoxic-ischaemic encephalopathy (LEVNEONAT-1): study protocol of a phase II trial. Bmj Open. 9: e022739. PMID 30679288 DOI: 10.1136/Bmjopen-2018-022739 |
0.392 |
|
| 2019 |
Aupiais C, Ursino M, Thomas S, Baud O, Zohar S, Alberti C. Une approche bayésienne de non-infériorité, utilisant des marges élicitées chez des experts, comme aide à la décision lors du monitoring d’événements secondaires rares Revue D'éPidéMiologie Et De Santé Publique. 67: S157. DOI: 10.1016/J.Respe.2019.03.035 |
0.453 |
|
| 2018 |
Soul JS, Pressler R, Allen M, Boylan G, Rabe H, Portman R, Hardy P, Zohar S, Romero K, Tseng B, Bhatt-Mehta V, Hahn C, Denne S, Auvin S, Vinks A, et al. Recommendations for the design of therapeutic trials for neonatal seizures. Pediatric Research. PMID 30584262 DOI: 10.1038/S41390-018-0242-2 |
0.417 |
|
| 2018 |
Berchialla P, Zohar S, Baldi I. Bayesian sample size determination for phase IIA clinical trials using historical data and semi-parametric prior's elicitation. Pharmaceutical Statistics. PMID 30440109 DOI: 10.1002/Pst.1914 |
0.413 |
|
| 2018 |
Friede T, Posch M, Zohar S, Alberti C, Benda N, Comets E, Day S, Dmitrienko A, Graf A, Günhan BK, Hee SW, Lentz F, Madan J, Miller F, Ondra T, et al. Recent advances in methodology for clinical trials in small populations: the InSPiRe project. Orphanet Journal of Rare Diseases. 13: 186. PMID 30359266 DOI: 10.1186/S13023-018-0919-Y |
0.594 |
|
| 2018 |
Aupiais C, Zohar S, Taverny G, Le Roux E, Boulkedid R, Alberti C. Exploring how non-inferiority and equivalence are assessed in paediatrics: a systematic review. Archives of Disease in Childhood. PMID 29794107 DOI: 10.1136/Archdischild-2018-314874 |
0.517 |
|
| 2018 |
Toumazi A, Comets E, Alberti C, Friede T, Lentz F, Stallard N, Zohar S, Ursino M. dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials. Computer Methods and Programs in Biomedicine. 157: 163-177. PMID 29477425 DOI: 10.1016/J.Cmpb.2018.01.023 |
0.646 |
|
| 2018 |
Pearce M, Hee SW, Madan J, Posch M, Day S, Miller F, Zohar S, Stallard N. Value of information methods to design a clinical trial in a small population to optimise a health economic utility function. Bmc Medical Research Methodology. 18: 20. PMID 29422021 DOI: 10.1186/S12874-018-0475-0 |
0.399 |
|
| 2018 |
Miller F, Zohar S, Stallard N, Madan J, Posch M, Hee SW, Pearce M, Vågerö M, Day S. Approaches to sample size calculation for clinical trials in rare diseases. Pharmaceutical Statistics. PMID 29322632 DOI: 10.1002/Pst.1848 |
0.317 |
|
| 2018 |
Ursino M, Yuan Y, Alberti C, Comets E, Favrais G, Friede T, Lentz F, Stallard N, Zohar S. A dose finding design for seizure reduction in neonates Journal of the Royal Statistical Society: Series C (Applied Statistics). 68: 427-444. DOI: 10.1111/Rssc.12289 |
0.621 |
|
| 2018 |
Beccaria K, Canney M, Bouchoux G, Zohar S, Boddaert N, Bourdeaut F, Doz F, Dufour C, Grill J, Carpentier A, Puget S. NSRG-05. SAFETY OF ULTRASOUND-INDUCED BLOOD-BRAIN BARRIER OPENING IN PEDIATRIC PATIENTS WITH REFRACTORY SUS-TENTORIAL MALIGNANT BRAIN TUMORS BEFORE CHEMOTHERAPY ADMINISTRATION – THE SONOKID CLINICAL TRIAL Neuro-Oncology. 20: i146-i146. DOI: 10.1093/Neuonc/Noy059.527 |
0.316 |
|
| 2017 |
Lee SM, Ursino M, Cheung YK, Zohar S. Dose-finding designs for cumulative toxicities using multiple constraints. Biostatistics (Oxford, England). PMID 29140414 DOI: 10.1093/Biostatistics/Kxx059 |
0.496 |
|
| 2017 |
Thall PF, Ursino M, Baudouin V, Alberti C, Zohar S. Bayesian treatment comparison using parametric mixture priors computed from elicited histograms. Statistical Methods in Medical Research. 962280217726803. PMID 28870123 DOI: 10.1177/0962280217726803 |
0.537 |
|
| 2017 |
Ursino M, Zohar S, Lentz F, Alberti C, Friede T, Stallard N, Comets E. Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations. Biometrical Journal. Biometrische Zeitschrift. PMID 28321893 DOI: 10.1002/Bimj.201600084 |
0.668 |
|
| 2017 |
Hee SW, Willis A, Tudur Smith C, Day S, Miller F, Madan J, Posch M, Zohar S, Stallard N. Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials.gov. Orphanet Journal of Rare Diseases. 12: 44. PMID 28253932 DOI: 10.1186/S13023-017-0597-1 |
0.426 |
|
| 2017 |
Rouzier R, Gouy S, Selle F, Lambaudie E, Floquet A, Fourchotte V, Pomel C, Colombo PE, Kalbacher E, Martin-Francoise S, Fauvet R, Follana P, Lesoin A, Lecuru F, Ghazi Y, ... ... Zohar S, et al. Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial. European Journal of Cancer (Oxford, England : 1990). 70: 133-142. PMID 27914243 DOI: 10.1016/J.Ejca.2016.09.036 |
0.307 |
|
| 2017 |
Ursino M, Thall P, Alberti C, Zohar S. Bayesian treatment comparison using parametric mixture priors based on histograms elicited from expert physicians Revue D'éPidéMiologie Et De Santé Publique. 65: S59-S60. DOI: 10.1016/J.Respe.2017.03.028 |
0.574 |
|
| 2016 |
Kaguelidou F, Alberti C, Biran V, Bourdon O, Farnoux C, Zohar S, Jacqz-Aigrain E. Dose-Finding Study of Omeprazole on Gastric pH in Neonates with Gastro-Esophageal Acid Reflux Using a Bayesian Sequential Approach. Plos One. 11: e0166207. PMID 28002471 DOI: 10.1371/Journal.Pone.0166207 |
0.59 |
|
| 2016 |
Petit C, Samson A, Morita S, Ursino M, Guedj J, Jullien V, Comets E, Zohar S. Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies. Statistical Methods in Medical Research. PMID 27705884 DOI: 10.1177/0962280216671348 |
0.474 |
|
| 2016 |
Stallard N, Miller F, Day S, Hee SW, Madan J, Zohar S, Posch M. Determination of the optimal sample size for a clinical trial accounting for the population size. Biometrical Journal. Biometrische Zeitschrift. PMID 27184938 DOI: 10.1002/Bimj.201500228 |
0.317 |
|
| 2016 |
Riviere MK, Yuan Y, Jourdan JH, Dubois F, Zohar S. Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization. Statistical Methods in Medical Research. PMID 26988926 DOI: 10.1177/0962280216631763 |
0.526 |
|
| 2016 |
Unkel S, Röver C, Stallard N, Benda N, Posch M, Zohar S, Friede T. Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions. Orphanet Journal of Rare Diseases. 11: 16. PMID 26897367 DOI: 10.1186/S13023-016-0402-6 |
0.334 |
|
| 2016 |
Riviere MK, Zohar S. Comments on 'A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies'. Statistics in Medicine. 35: 475-8. PMID 26757957 DOI: 10.1002/Sim.6630 |
0.495 |
|
| 2016 |
Riviere MK, Jourdan JH, Zohar S. dfcomb: An R-package for phase I/II trials of drug combinations. Computer Methods and Programs in Biomedicine. 125: 117-33. PMID 26652977 DOI: 10.1016/J.Cmpb.2015.10.018 |
0.456 |
|
| 2016 |
Moatti M, Chevret S, Zohar S, Rosenberger WF. A Bayesian hybrid adaptive randomisation design for clinical trials with survival outcomes Methods of Information in Medicine. 55: 4-13. DOI: 10.3414/Me14-01-0132 |
0.577 |
|
| 2016 |
Riviere MK, Zohar S. Comments on 'A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies' Statistics in Medicine. 35: 475-478. DOI: 10.1002/sim.6630 |
0.4 |
|
| 2015 |
Petit C, Jullien V, Samson A, Guedj J, Kiechel JR, Zohar S, Comets E. Designing a Pediatric Study for an Antimalarial Drug by Using Information from Adults. Antimicrobial Agents and Chemotherapy. 60: 1481-91. PMID 26711749 DOI: 10.1128/Aac.01125-15 |
0.324 |
|
| 2015 |
Hee SW, Hamborg T, Day S, Madan J, Miller F, Posch M, Zohar S, Stallard N. Decision-theoretic designs for small trials and pilot studies: A review. Statistical Methods in Medical Research. PMID 26048902 DOI: 10.1177/0962280215588245 |
0.422 |
|
| 2015 |
Teramukai S, Daimon T, Zohar S. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety. Statistics in Medicine. 34: 3029-39. PMID 26038148 DOI: 10.1002/Sim.6550 |
0.425 |
|
| 2015 |
Pressler RM, Boylan GB, Marlow N, Blennow M, Chiron C, Cross JH, de Vries LS, Hallberg B, Hellström-Westas L, Jullien V, Livingstone V, Mangum B, Murphy B, Murray D, Pons G, ... ... Zohar S, et al. Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial. The Lancet. Neurology. 14: 469-77. PMID 25765333 DOI: 10.1016/S1474-4422(14)70303-5 |
0.4 |
|
| 2015 |
Riviere MK, Dubois F, Zohar S. Response to comments on 'competing designs for drug combination in phase I dose-finding clinical trials' by G. Yin, R. Lin and N. Wages. Statistics in Medicine. 34: 23-6. PMID 25492617 DOI: 10.1002/Sim.6332 |
0.445 |
|
| 2015 |
Riviere MK, Le Tourneau C, Paoletti X, Dubois F, Zohar S. Designs of drug-combination phase I trials in oncology: a systematic review of the literature. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 669-74. PMID 25403591 DOI: 10.1093/Annonc/Mdu516 |
0.412 |
|
| 2015 |
Riviere MK, Dubois F, Zohar S. Competing designs for drug combination in phase I dose-finding clinical trials. Statistics in Medicine. 34: 1-12. PMID 24464821 DOI: 10.1002/Sim.6094 |
0.505 |
|
| 2015 |
Rouzier R, Gouy S, Selle F, Lambaudie E, Guyon F, Fourchotte V, Pomel C, Colombo PE, Kalbacher E, Martin S, Fauvet R, Follana P, Lesoin A, Lecuru F, Menguy V, ... ... Zohar S, et al. Correlation of baseline clinical characteristics and laparoscopic extent of carcinomatosis of women with initially unresectable ovarian, tubal or peritoneal adenocarcinoma, in ANTHALYA study: A randomized, open-label, phase II study assessing the efficacy and the safety of bevacizumab in neoadjuvant. Journal of Clinical Oncology. 33: 5538-5538. DOI: 10.1200/Jco.2015.33.15_Suppl.5538 |
0.428 |
|
| 2015 |
Riviere M-, Yuan Y, Dubois F, Zohar S. A Bayesian dose finding design for clinical trials combining a cytotoxic agent with a molecularly targeted agent Journal of the Royal Statistical Society Series C-Applied Statistics. 64: 215-229. DOI: 10.1111/Rssc.12072 |
0.501 |
|
| 2015 |
Selle F, Gouy S, Lambaudie E, Guyon F, Fourchotte V, Pomel C, Colombo P, Kalbacher E, Martin-Francoise S, Fauvet R, Follana P, Lesoin A, Lecuru F, Menguy V, Ghazi Y, ... ... Zohar S, et al. 2766 Safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Data from the ANTHALYA trial European Journal of Cancer. 51: S553. DOI: 10.1016/S0959-8049(16)31532-5 |
0.318 |
|
| 2015 |
Andriss B, Husson I, Guilmin Crepon S, Jacqz-Aigrain E, Zohar S, Alberti C. Application de la méthodologie bayésienne a un essai clinique de petit effectif. Exemple de l’essai ACTFRIE : étude de l’effet de la pioglitazone dans l’ataxie de Friedreich Revue D'éPidéMiologie Et De Santé Publique. 63: S63. DOI: 10.1016/J.Respe.2015.03.058 |
0.382 |
|
| 2014 |
Thall PF, Nguyen HQ, Zohar S, Maton P. Optimizing Sedative Dose in Preterm Infants Undergoing Treatment for Respiratory Distress Syndrome. Journal of the American Statistical Association. 109: 931-943. PMID 25368435 DOI: 10.1080/01621459.2014.904789 |
0.363 |
|
| 2014 |
Riviere MK, Yuan Y, Dubois F, Zohar S. A Bayesian dose-finding design for drug combination clinical trials based on the logistic model. Pharmaceutical Statistics. 13: 247-57. PMID 24828456 DOI: 10.1002/Pst.1621 |
0.518 |
|
| 2013 |
Moatti M, Zohar S, Facon T, Moreau P, Mary JY, Chevret S. Modeling of experts' divergent prior beliefs for a sequential phase III clinical trial. Clinical Trials (London, England). 10: 505-14. PMID 23820061 DOI: 10.1177/1740774513493528 |
0.499 |
|
| 2013 |
Daimon T, Zohar S. An adaptive model switching approach for phase I dose-finding trials. Pharmaceutical Statistics. 12: 225-32. PMID 23801550 DOI: 10.1002/Pst.1578 |
0.485 |
|
| 2013 |
Kant A, Gupta PK, Zohar S, Chevret S, Hopkins PM. Application of the continual reassessment method to dose-finding studies in regional anesthesia: an estimate of the ED95 dose for 0.5% bupivacaine for ultrasound-guided supraclavicular block. Anesthesiology. 119: 29-35. PMID 23648519 DOI: 10.1097/Aln.0B013E31829764Cf |
0.562 |
|
| 2013 |
Ezzalfani M, Zohar S, Qin R, Mandrekar SJ, Deley MC. Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities. Statistics in Medicine. 32: 2728-46. PMID 23335156 DOI: 10.1002/Sim.5737 |
0.488 |
|
| 2013 |
Zohar S, Resche-Rigon M, Chevret S. Using the continual reassessment method to estimate the minimum effective dose in phase II dose-finding studies: a case study. Clinical Trials (London, England). 10: 414-21. PMID 21824977 DOI: 10.1177/1740774511411593 |
0.713 |
|
| 2013 |
Teramukai S, Daimon T, Zohar S. A new design for phase II single-arm clinical trials: Bayesian predictive sample size selection design. Journal of Clinical Oncology. 31: 6576-6576. DOI: 10.1200/Jco.2013.31.15_Suppl.6576 |
0.459 |
|
| 2013 |
Ezzalfani M, Zohar S, Mandrekar SJ, Vassal G, Deley ML. Novel toxicity endpoint for dose-finding designs evaluating molecularly targeted agents (MTA). Journal of Clinical Oncology. 31: 2577-2577. DOI: 10.1200/Jco.2013.31.15_Suppl.2577 |
0.454 |
|
| 2012 |
Iasonos A, Gounder M, Spriggs DR, Gerecitano JF, Hyman DM, Zohar S, O'Quigley J. The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5179-87. PMID 22825582 DOI: 10.1158/1078-0432.Ccr-12-0726 |
0.415 |
|
| 2012 |
Chirica M, Resche-Rigon M, Bongrand NM, Zohar S, Halimi B, Gornet JM, Sarfati E, Cattan P. Surgery for caustic injuries of the upper gastrointestinal tract. Annals of Surgery. 256: 994-1001. PMID 22824850 DOI: 10.1097/Sla.0B013E3182583Fb2 |
0.475 |
|
| 2012 |
Teramukai S, Daimon T, Zohar S. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials. Statistics in Medicine. 31: 4243-54. PMID 22807115 DOI: 10.1002/Sim.5505 |
0.429 |
|
| 2012 |
Chereau E, Uzan C, Zohar S, Bezu C, Mazouni C, Ballester M, Gouy S, Rimareix F, Garbay J, Darai E, Uzan S, Rouzier R. Abstract P4-14-12: Evaluation of the effect of pasireotide LAR administration in the lymphocele prevention after mastectomy with axillary lymph node dissection for breast cancer: results of a phase 2 randomized study. Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P4-14-12 |
0.396 |
|
| 2011 |
Iasonos A, Zohar S, O'Quigley J. Incorporating lower grade toxicity information into dose finding designs. Clinical Trials (London, England). 8: 370-9. PMID 21835856 DOI: 10.1177/1740774511410732 |
0.434 |
|
| 2011 |
Mauguen A, Le Deley MC, Zohar S. Dose-finding approach for dose escalation with overdose control considering incomplete observations. Statistics in Medicine. 30: 1584-94. PMID 21351289 DOI: 10.1002/Sim.4128 |
0.492 |
|
| 2011 |
Daimon T, Zohar S, O'Quigley J. Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method Statistics in Medicine. 30: 1563-1573. PMID 21351288 DOI: 10.1002/Sim.4054 |
0.385 |
|
| 2011 |
Zohar S, Katsahian S, O'Quigley J. An approach to meta-analysis of dose-finding studies. Statistics in Medicine. 30: 2109-16. PMID 21344473 DOI: 10.1002/Sim.4121 |
0.704 |
|
| 2011 |
Zohar S, Baldi I, Forni G, Merletti F, Masucci G, Gregori D. Planning a Bayesian early-phase phase I/II study for human vaccines in HER2 carcinomas Pharmaceutical Statistics. 10: 218-226. PMID 20922817 DOI: 10.1002/Pst.450 |
0.512 |
|
| 2011 |
Ezzalfani M, Le Deley M, Zohar S. Étude de comparaison des différentes méthodes de recherche de dose en oncologie, avec prise en compte de toxicités modérées et gradées Revue D'éPidéMiologie Et De Santé Publique. 59: S12-S13. DOI: 10.1016/J.Respe.2011.02.084 |
0.337 |
|
| 2010 |
O'Quigley J, Zohar S. Retrospective robustness of the continual reassessment method. Journal of Biopharmaceutical Statistics. 20: 1013-25. PMID 20721788 DOI: 10.1080/10543400903315732 |
0.387 |
|
| 2010 |
Carpentier A, Metellus P, Ursu R, Zohar S, Lafitte F, Barrié M, Meng Y, Richard M, Parizot C, Laigle-Donadey F, Gorochov G, Psimaras D, Sanson M, Tibi A, Chinot O, et al. Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro-Oncology. 12: 401-8. PMID 20308317 DOI: 10.1093/Neuonc/Nop047 |
0.4 |
|
| 2010 |
Iasonos A, Zohar S, O'Quigley J. Impact of miscoding dose-limiting toxicities in dose-escalation phase I studies. Journal of Clinical Oncology. 28: e13007-e13007. DOI: 10.1200/Jco.2010.28.15_Suppl.E13007 |
0.446 |
|
| 2009 |
Zohar S, O'Quigley J. Re: Dose escalation methods in phase I cancer clinical trials. Journal of the National Cancer Institute. 101: 1732-3; author reply. PMID 19893006 DOI: 10.1093/jnci/djp400 |
0.394 |
|
| 2009 |
Zohar S, Medioni J, Lebbé C, Avril MF, Kerob D, Eftekhari P, Driheme A, Lebras KC, Bruzzoni-Giovanelli H, Levy V, Chevret S, Calvo F. Interest in an original methodology to define the optimal dosage of interferon-alpha-2a in metastatic melanoma patients. Melanoma Research. 19: 379-84. PMID 19858763 DOI: 10.1097/Cmr.0B013E3283281042 |
0.685 |
|
| 2009 |
Comets E, Zohar S. A survey of the way pharmacokinetics are reported in published phase I clinical trials, with an emphasis on oncology. Clinical Pharmacokinetics. 48: 387-95. PMID 19650677 DOI: 10.2165/00003088-200948060-00004 |
0.482 |
|
| 2009 |
Zohar S, O'Quigley J. Sensitivity of dose-finding studies to observation errors. Contemporary Clinical Trials. 30: 523-30. PMID 19580886 DOI: 10.1016/J.Cct.2009.06.008 |
0.488 |
|
| 2009 |
Merlin E, Zohar S, Jérôme C, Veyrat-Masson R, Marceau G, Paillard C, Auvrignon A, Le Moine P, Gandemer V, Sapin V, Halle P, Boiret-Dupré N, Chevret S, Deméocq F, Dubray C, et al. Hematopoietic progenitor cell mobilization and harvesting in children with malignancies: do the advantages of pegfilgrastim really translate into clinical benefit? Bone Marrow Transplantation. 43: 919-25. PMID 19104490 DOI: 10.1038/Bmt.2008.412 |
0.347 |
|
| 2008 |
Resche-Rigon M, Zohar S, Chevret S. Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes. Clinical Trials (London, England). 5: 595-606. PMID 19029208 DOI: 10.1177/1740774508098788 |
0.715 |
|
| 2008 |
Zohar S, Lian Q, Levy V, Cheung K, Ivanova A, Chevret S. Quality assessment of phase I dose-finding cancer trials: proposal of a checklist. Clinical Trials (London, England). 5: 478-85. PMID 18827040 DOI: 10.1177/1740774508096653 |
0.699 |
|
| 2008 |
Zohar S, Teramukai S, Zhou Y. Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: a tutorial. Contemporary Clinical Trials. 29: 608-16. PMID 18201945 DOI: 10.1016/J.Cct.2007.11.005 |
0.487 |
|
| 2008 |
Zohar S, Levy V. Dose Estimation A Key Step in Malignancies Drug Development Pharmaceutical Medicine. 22: 35-40. DOI: 10.1007/Bf03256680 |
0.681 |
|
| 2007 |
Zohar S, Chevret S. Recent developments in adaptive designs for Phase I/II dose-finding studies. Journal of Biopharmaceutical Statistics. 17: 1071-83. PMID 18027217 DOI: 10.1080/10543400701645116 |
0.63 |
|
| 2006 |
Zohar S, O'Quigley J. Identifying the most successful dose (MSD) in dose-finding studies in cancer. Pharmaceutical Statistics. 5: 187-99. PMID 17080752 DOI: 10.1002/Pst.209 |
0.408 |
|
| 2006 |
Zohar S, O'Quigley J. Optimal designs for estimating the most successful dose. Statistics in Medicine. 25: 4311-20. PMID 16969893 DOI: 10.1002/Sim.2685 |
0.469 |
|
| 2006 |
Lévy V, Zohar S, Bardin C, Vekhoff A, Chaoui D, Rio B, Legrand O, Sentenac S, Rousselot P, Raffoux E, Chast F, Chevret S, Marie JP. A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia. British Journal of Cancer. 95: 253-9. PMID 16847470 DOI: 10.1038/Sj.Bjc.6603265 |
0.669 |
|
| 2006 |
Lefrère F, Zohar S, Bresson JL, Chevret S, Mogenet A, Audat F, Durand-Zaleski I, Ghez D, Dal Cortivo L, Piesvaux P, Cavazzana-Calvo M, Varet B. A double-blind low dose-finding phase II study of granulocyte colony-stimulating factor combined with chemotherapy for stem cell mobilization in patients with non-Hodgkin's lymphoma. Haematologica. 91: 550-3. PMID 16585020 |
0.514 |
|
| 2006 |
Lefrère F, Zohar S, Ghez D, Delarue R, Audat F, Suarez F, Hermine O, Damaj G, Maillard N, Ribeil JA, Azagury M, Misbahi R, Jondeau K, Cavazzana-Calvo M, Dal Cortivo L, et al. The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients. Bone Marrow Transplantation. 37: 725-9. PMID 16518433 DOI: 10.1038/Sj.Bmt.1705308 |
0.336 |
|
| 2006 |
Carpentier A, Laigle-Donadey F, Zohar S, Capelle L, Behin A, Tibi A, Martin-Duverneuil N, Sanson M, Lacomblez L, Taillibert S, Puybasset L, Van Effenterre R, Delattre JY, Carpentier AF. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro-Oncology. 8: 60-6. PMID 16443949 DOI: 10.1215/S1522851705000475 |
0.409 |
|
| 2006 |
O'Quigley J, Zohar S. Experimental designs for phase I and phase I/II dose-finding studies. British Journal of Cancer. 94: 609-613. PMID 16434987 DOI: 10.1038/Sj.Bjc.6602969 |
0.441 |
|
| 2005 |
Treluyer JM, Zohar S, Rey E, Hubert P, Iserin F, Jugie M, Lenclen R, Chevret S, Pons G. Minimum effective dose of midazolam for sedation of mechanically ventilated neonates. Journal of Clinical Pharmacy and Therapeutics. 30: 479-85. PMID 16164495 DOI: 10.1111/J.1365-2710.2005.00678.X |
0.522 |
|
| 2005 |
Desfrere L, Zohar S, Morville P, Brunhes A, Chevret S, Pons G, Moriette G, Rey E, Treluyer JM. Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. Journal of Clinical Pharmacy and Therapeutics. 30: 121-32. PMID 15811164 DOI: 10.1111/J.1365-2710.2005.00630.X |
0.564 |
|
| 2003 |
Zohar S, Latouche A, Taconnet M, Chevret S. Software to compute and conduct sequential Bayesian phase I or II dose-ranging clinical trials with stopping rules. Computer Methods and Programs in Biomedicine. 72: 117-25. PMID 12941516 DOI: 10.1016/S0169-2607(02)00120-7 |
0.762 |
|
| 2003 |
Zohar S, Chevret S. Phase I (or phase II) dose-ranging clinical trials: proposal of a two-stage Bayesian design. Journal of Biopharmaceutical Statistics. 13: 87-101. PMID 12635905 DOI: 10.1081/Bip-120017728 |
0.642 |
|
| 2002 |
Farge D, Marolleau JP, Zohar S, Marjanovic Z, Cabane J, Mounier N, Hachulla E, Philippe P, Sibilia J, Rabian C, Chevret S, Gluckman E. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study. British Journal of Haematology. 119: 726-39. PMID 12437652 DOI: 10.1046/J.1365-2141.2002.03895.X |
0.469 |
|
| 2001 |
Zohar S, Chevret S. The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies. Statistics in Medicine. 20: 2827-43. PMID 11568943 DOI: 10.1002/Sim.920 |
0.625 |
|
| 2001 |
Lévy V, Zohar S, Porcher R, Chevret S. Alternate designs for conduct and analysis of phase I cancer trials. Blood. 98: 1275-6. PMID 11510472 DOI: 10.1182/Blood.V98.4.1275 |
0.676 |
|
| Show low-probability matches. |